Metraipolis › archive › dc_8bc2d51e2e93

Efficacy of Tislelizumab plus Lenvatinib in hepatocellular carcinoma after curative hepatectomy: a real-world study — Europe PMC PMID:41050706

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41050706
DOI
10.3389/fimmu.2025.1652717
License (as archived)
solo-consultazione
Archived
2026-11-09T21:42:38.035Z
SHA-256 of the archived text
ccae6ea51ed6e85e693b39d693e654469ef684b1f134302f9e9c90a75dd06ecb
Stable URL of this page
https://metraipolis.com/documento/dc_8bc2d51e2e93

How to cite

Efficacy of Tislelizumab plus Lenvatinib in hepatocellular carcinoma after curative hepatectomy: a real-world study — Europe PMC PMID:41050706 — Europe PMC (en), https://europepmc.org/article/MED/41050706 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_8bc2d51e2e93 (Metraipolis archive dc_8bc2d51e2e93, sha256 ccae6ea51ed6e85e693b39d693e654469ef684b1f134302f9e9c90a75dd06ecb)
BibTeX
@misc{dc8bc2d51e2e93,
  title = {Efficacy of Tislelizumab plus Lenvatinib in hepatocellular carcinoma after curative hepatectomy: a real-world study — Europe PMC PMID:41050706},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41050706},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_8bc2d51e2e93; sha256 ccae6ea51ed6e85e693b39d693e654469ef684b1f134302f9e9c90a75dd06ecb},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41050706. Agents can read the archived copy with the MCP tool read_document.